Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts

Zagazig University39 enrolled

Overview

The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.

39 patients are enrolled in the study They suffer from chronic recurrent cutaneous warts Patients receive Candida antigen immunotherapy vial intra-lesional injection every 2 weeks till complete resolution or the maximum of 5 sessions Blood samples are withdrawn before and after intervention C3, C4, MBL, C3C and TNF alpha serum levels are measured

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Warts

Interventions

Candida antigenBIOLOGICAL

Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention

Eligibility

Sex: ALLMin age: 9 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic multiple cutaneous Exclusion Criteria: * Hypersensitivity to Candida antigen * Fever * Immunosuppressive disorders * Previous wart therapy in the last month

Locations (1)

Zagazig University Faculty of Medicine

Zagazig, Sharqia Province, Egypt

Outcomes

Primary Outcomes

Resolution of warts

100% clearance of warts

Time frame: 12 weeks

Secondary Outcomes

Recurrence

Reappearance of warts

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.